Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Identification of intrinsically immunogenic small cell lung carcinoma (SCLC) subpopulations

ABSTRACT: Identification of intrinsically immunogenic small cell lung carcinoma (SCLC) subpopulations

PROVIDER: PRJNA706431 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR13849983_1.fastq.gz	Fastqsanger.gz
	SRR13849983_2.fastq.gz	Fastqsanger.gz
	SRR13849984_1.fastq.gz	Fastqsanger.gz
	SRR13849984_2.fastq.gz	Fastqsanger.gz
	SRR13849985_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Identification of intrinsically immunogenic small cell lung carcinoma (SCLC) subpopulations

Project description:Identification of intrinsically immunogenic small cell lung carcinoma (SCLC) subpopulations

| PRJNA706756 | ENA

Identification of intrinsically immunogenic small cell lung carcinoma (SCLC) subpopulations [patient]

Project description:Identification of intrinsically immunogenic small cell lung carcinoma (SCLC) subpopulations [patient]

| PRJNA706705 | ENA

Identification of intrinsically immunogenic small cell lung carcinoma (SCLC) subpopulations [Cell line]

Project description:Identification of intrinsically immunogenic small cell lung carcinoma (SCLC) subpopulations [Cell line]

| PRJNA706757 | ENA

Identification of intrinsically immunogenic small cell lung carcinoma (SCLC) subpopulations

Project description:SCLC is molecularly and immunologically heterogenous. Here, using transcriptional and epigenomic profiling of plastic SCLC states in human and mouse cell lines, and patient samples, we define the phenotype of a SCLC population marked by increased MHC Class I antigen presentation.

2021-03-04 | GSE168195 | GEO

Identification of intrinsically immunogenic small cell lung carcinoma (SCLC) subpopulations [patient]

2021-03-05 | GSE168266 | GEO

Identification of intrinsically immunogenic small cell lung carcinoma (SCLC) subpopulations [Cell line]

2021-03-05 | GSE168294 | GEO

Identification of intrinsically immunogenic small cell lung carcinoma (SCLC) subpopulations

Project description:This SuperSeries is composed of the SubSeries listed below.

2021-03-05 | GSE168295 | GEO

Quantitative Proteomics Analysis of Extracellular Vesicles from mouse-derived SCLC cell lines

Project description:Small Cell Lung Cancer (SCLC) tumors are made up of distinct cell subpopulations, including neuroendocrine (NE) and non-NE cells. Proteomic analysis of purified small extracellular vesicles (EV) from these two cell populations were conducted.

2023-11-01 | PXD042153 | Pride

EIF6 conditions drug-tolerant persister-like transdifferentiation in small cell lung carcinoma (SCLC cell lines)

Project description:Drug-tolerant persister cells withstand treatments by adapting their identity through lineage-dependent plasticity during systemic anti-cancer therapies. This phenomenon is evident in small-cell lung carcinoma (SCLC), a lethal neuroendocrine cancer initially responsive (60-80%) to platinum-based chemotherapy but succumbing to resistance within 6 months in advanced stages. This resistance associates with the transdifferentiation of residual tumour cells into a non-neuroendocrine state, a process intricately tied to SCLC's chemotolerance, yet molecular mechanisms governing this lineage conversion remain completed understood. Here we use paired cytoplasmic RNA-seq and polysomal RNA-seq to compare gene expression between NE and non-NE SCLC cell lines on both transcriptional and translational level. We report that first-line chemotherapy induces translation initiation factor eIF6 in drug-tolerant persister-like cells in SCLC, correlating with the non-neuroendocrine state in SCLC. Intervening eIF6 inhibits non-neuroendocrine transdifferentiation, thus enhancing SCLC responsiveness to chemotherapy. This study sheds light on eIF6's potential therapeutic interventions to mitigate treatment resistance in SCLC.

2024-04-30 | GSE262593 | GEO

The RNAseq of 79 small cell lung cancer (sclc) and 7 normal control

Project description:Even though small cell lung cancer (SCLC) has entered the age of broad genomic analysis, platinum-based chemotherapy remains the standard care for SCLC. Topotecan is the only approved agent for recurrent or progressive SCLC (1). In the absence of well-defined genomic biomarkers, clinical efficacy signals in genomically distinct subsets of SCLC could have been missed. Serine/Arginine Splicing Factor 1 (SRSF1) is a member of SR protein family. The deleterious consequences of overexpression of the SRSF1 proto-oncogene in human cancers suggest that there are complex mechanisms and pathways underlying SRSF1-mediated transformation (2). Whole exome and transcriptome sequencing of primary tumor SCLC from 99 Chinese patients has identified SRSF1 DNA amplification and mRNA over-expression which predicts poor survival in Chinese SCLC patients. In vitro and in vivo studies have demonstrated that SRSF1 is essential for tumorigenecity of SCLC and plays a key role in DNA repair and chemo-sensitivity. We did RNAseq on 79 small cell lung cancer patients' tumor sample and 7 normal lung tissue. We normalized the RNAseq data and did differential expression analysis. The deleterious consequences of overexpression of the SRSF1 proto-oncogene in human cancers suggest that there are complex mechanisms and pathways underlying SRSF1-mediated transformation.

2016-02-10 | E-GEOD-60052 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data